Guest guest Posted April 1, 2011 Report Share Posted April 1, 2011 News 8 new results for Hepatitis New Drug May Boost Hepatitis C Treatment BusinessWeek By Reinberg WEDNESDAY, March 30 (HealthDay News) -- Adding the new drug boceprevir to the current two-drug treatment for hepatitis C appears significantly more effective than the standard therapy, according to two new studies. ... See all stories on this topic » Vertex Pharma's Telaprevir Improves Viral Cure Rates In Hepatitis C RTT News (RTTNews) - Vertex Pharmaceuticals Inc. (VRTX: News ), said Thursday its Telaprevir-based therapy significantly improved viral cure rates in Hepatitis C patients whose prior treatment with pegylated-interferon and ribavirin was unsuccessful. ... See all stories on this topic » REG-Novartis first-in-class antiviral DEB025 achieved sustained viral response .... Reuters (press release) The study involved nearly 300 previously untreated patients infected with the most common form of hepatitis C virus (HCV), the genotype 1 (G1)[1]. The data were presented today at the European Association for the Study of the Liver (EASL) congress in ... See all stories on this topic » Cirrhosis and HCC Have Risen Dramatically in Hepatitis C Patients Internal Medicine News Digital Network The burden of cirrhosis, hepatic decompensation, and hepatocellular carcinoma has risen dramatically during the past decade among patients with chronic hepatitis C virus infection, Dr. Fasiha Kanwal and her colleagues reported in the April issue of ... See all stories on this topic » OctoPlus' licensee Biolex presents Phase IIb results at EASL showing reduced ... Reuters (press release) In combination with its reduced injection frequency, these benefits clearly position Locteron as the interferon of choice for future hepatitis C treatments. " The following information was taken directly from Biolex' press release (see www.biolex.com). ... See all stories on this topic » Hope for liver patients Worcester Telegram By Nugent TELEGRAM & GAZETTE STAFF Dr. Heidi L. of the University of Massachusetts Medical School is performing trials for a new hepatitis C antibody. (T & G Staff/TOM RETTIG) WORCESTER — A new liver does not mean the end of hepatitis C. The ... See all stories on this topic » Adverse event profile of regimen containing BMS-790052 was consistent with ... Benzinga “There currently exists a medical need for new medicines or new combinations of medicines for hepatitis C patients as many hepatitis C patients have limited success on the currently available treatments,” said Stanislas Pol, MD, PhD, Professor of ... See all stories on this topic » Fluvastatin Enhances Chronic Hepatitis C Treatment Response in Combination ... PR Newswire UK (press release) New data presented today at the International Liver Congress confirm the antiviral activity of fluvastatin - commonly used as a cholesterol-lowering treatment - in patients with chronic hepatitis C (HCV).[1] Patients had improved early and ... See all stories on this topic » Tip: Use a plus sign (+) to match a term in your query exactly as is. Learn more. .. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 1, 2011 Report Share Posted April 1, 2011 News 8 new results for Hepatitis New Drug May Boost Hepatitis C Treatment BusinessWeek By Reinberg WEDNESDAY, March 30 (HealthDay News) -- Adding the new drug boceprevir to the current two-drug treatment for hepatitis C appears significantly more effective than the standard therapy, according to two new studies. ... See all stories on this topic » Vertex Pharma's Telaprevir Improves Viral Cure Rates In Hepatitis C RTT News (RTTNews) - Vertex Pharmaceuticals Inc. (VRTX: News ), said Thursday its Telaprevir-based therapy significantly improved viral cure rates in Hepatitis C patients whose prior treatment with pegylated-interferon and ribavirin was unsuccessful. ... See all stories on this topic » REG-Novartis first-in-class antiviral DEB025 achieved sustained viral response .... Reuters (press release) The study involved nearly 300 previously untreated patients infected with the most common form of hepatitis C virus (HCV), the genotype 1 (G1)[1]. The data were presented today at the European Association for the Study of the Liver (EASL) congress in ... See all stories on this topic » Cirrhosis and HCC Have Risen Dramatically in Hepatitis C Patients Internal Medicine News Digital Network The burden of cirrhosis, hepatic decompensation, and hepatocellular carcinoma has risen dramatically during the past decade among patients with chronic hepatitis C virus infection, Dr. Fasiha Kanwal and her colleagues reported in the April issue of ... See all stories on this topic » OctoPlus' licensee Biolex presents Phase IIb results at EASL showing reduced ... Reuters (press release) In combination with its reduced injection frequency, these benefits clearly position Locteron as the interferon of choice for future hepatitis C treatments. " The following information was taken directly from Biolex' press release (see www.biolex.com). ... See all stories on this topic » Hope for liver patients Worcester Telegram By Nugent TELEGRAM & GAZETTE STAFF Dr. Heidi L. of the University of Massachusetts Medical School is performing trials for a new hepatitis C antibody. (T & G Staff/TOM RETTIG) WORCESTER — A new liver does not mean the end of hepatitis C. The ... See all stories on this topic » Adverse event profile of regimen containing BMS-790052 was consistent with ... Benzinga “There currently exists a medical need for new medicines or new combinations of medicines for hepatitis C patients as many hepatitis C patients have limited success on the currently available treatments,” said Stanislas Pol, MD, PhD, Professor of ... See all stories on this topic » Fluvastatin Enhances Chronic Hepatitis C Treatment Response in Combination ... PR Newswire UK (press release) New data presented today at the International Liver Congress confirm the antiviral activity of fluvastatin - commonly used as a cholesterol-lowering treatment - in patients with chronic hepatitis C (HCV).[1] Patients had improved early and ... See all stories on this topic » Tip: Use a plus sign (+) to match a term in your query exactly as is. Learn more. .. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 1, 2011 Report Share Posted April 1, 2011 News 8 new results for Hepatitis New Drug May Boost Hepatitis C Treatment BusinessWeek By Reinberg WEDNESDAY, March 30 (HealthDay News) -- Adding the new drug boceprevir to the current two-drug treatment for hepatitis C appears significantly more effective than the standard therapy, according to two new studies. ... See all stories on this topic » Vertex Pharma's Telaprevir Improves Viral Cure Rates In Hepatitis C RTT News (RTTNews) - Vertex Pharmaceuticals Inc. (VRTX: News ), said Thursday its Telaprevir-based therapy significantly improved viral cure rates in Hepatitis C patients whose prior treatment with pegylated-interferon and ribavirin was unsuccessful. ... See all stories on this topic » REG-Novartis first-in-class antiviral DEB025 achieved sustained viral response .... Reuters (press release) The study involved nearly 300 previously untreated patients infected with the most common form of hepatitis C virus (HCV), the genotype 1 (G1)[1]. The data were presented today at the European Association for the Study of the Liver (EASL) congress in ... See all stories on this topic » Cirrhosis and HCC Have Risen Dramatically in Hepatitis C Patients Internal Medicine News Digital Network The burden of cirrhosis, hepatic decompensation, and hepatocellular carcinoma has risen dramatically during the past decade among patients with chronic hepatitis C virus infection, Dr. Fasiha Kanwal and her colleagues reported in the April issue of ... See all stories on this topic » OctoPlus' licensee Biolex presents Phase IIb results at EASL showing reduced ... Reuters (press release) In combination with its reduced injection frequency, these benefits clearly position Locteron as the interferon of choice for future hepatitis C treatments. " The following information was taken directly from Biolex' press release (see www.biolex.com). ... See all stories on this topic » Hope for liver patients Worcester Telegram By Nugent TELEGRAM & GAZETTE STAFF Dr. Heidi L. of the University of Massachusetts Medical School is performing trials for a new hepatitis C antibody. (T & G Staff/TOM RETTIG) WORCESTER — A new liver does not mean the end of hepatitis C. The ... See all stories on this topic » Adverse event profile of regimen containing BMS-790052 was consistent with ... Benzinga “There currently exists a medical need for new medicines or new combinations of medicines for hepatitis C patients as many hepatitis C patients have limited success on the currently available treatments,” said Stanislas Pol, MD, PhD, Professor of ... See all stories on this topic » Fluvastatin Enhances Chronic Hepatitis C Treatment Response in Combination ... PR Newswire UK (press release) New data presented today at the International Liver Congress confirm the antiviral activity of fluvastatin - commonly used as a cholesterol-lowering treatment - in patients with chronic hepatitis C (HCV).[1] Patients had improved early and ... See all stories on this topic » Tip: Use a plus sign (+) to match a term in your query exactly as is. Learn more. .. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 1, 2011 Report Share Posted April 1, 2011 News 8 new results for Hepatitis New Drug May Boost Hepatitis C Treatment BusinessWeek By Reinberg WEDNESDAY, March 30 (HealthDay News) -- Adding the new drug boceprevir to the current two-drug treatment for hepatitis C appears significantly more effective than the standard therapy, according to two new studies. ... See all stories on this topic » Vertex Pharma's Telaprevir Improves Viral Cure Rates In Hepatitis C RTT News (RTTNews) - Vertex Pharmaceuticals Inc. (VRTX: News ), said Thursday its Telaprevir-based therapy significantly improved viral cure rates in Hepatitis C patients whose prior treatment with pegylated-interferon and ribavirin was unsuccessful. ... See all stories on this topic » REG-Novartis first-in-class antiviral DEB025 achieved sustained viral response .... Reuters (press release) The study involved nearly 300 previously untreated patients infected with the most common form of hepatitis C virus (HCV), the genotype 1 (G1)[1]. The data were presented today at the European Association for the Study of the Liver (EASL) congress in ... See all stories on this topic » Cirrhosis and HCC Have Risen Dramatically in Hepatitis C Patients Internal Medicine News Digital Network The burden of cirrhosis, hepatic decompensation, and hepatocellular carcinoma has risen dramatically during the past decade among patients with chronic hepatitis C virus infection, Dr. Fasiha Kanwal and her colleagues reported in the April issue of ... See all stories on this topic » OctoPlus' licensee Biolex presents Phase IIb results at EASL showing reduced ... Reuters (press release) In combination with its reduced injection frequency, these benefits clearly position Locteron as the interferon of choice for future hepatitis C treatments. " The following information was taken directly from Biolex' press release (see www.biolex.com). ... See all stories on this topic » Hope for liver patients Worcester Telegram By Nugent TELEGRAM & GAZETTE STAFF Dr. Heidi L. of the University of Massachusetts Medical School is performing trials for a new hepatitis C antibody. (T & G Staff/TOM RETTIG) WORCESTER — A new liver does not mean the end of hepatitis C. The ... See all stories on this topic » Adverse event profile of regimen containing BMS-790052 was consistent with ... Benzinga “There currently exists a medical need for new medicines or new combinations of medicines for hepatitis C patients as many hepatitis C patients have limited success on the currently available treatments,” said Stanislas Pol, MD, PhD, Professor of ... See all stories on this topic » Fluvastatin Enhances Chronic Hepatitis C Treatment Response in Combination ... PR Newswire UK (press release) New data presented today at the International Liver Congress confirm the antiviral activity of fluvastatin - commonly used as a cholesterol-lowering treatment - in patients with chronic hepatitis C (HCV).[1] Patients had improved early and ... See all stories on this topic » Tip: Use a plus sign (+) to match a term in your query exactly as is. Learn more. .. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.